{"schema_version":"secwatch.filing_event.v1","accession":"0001396814-25-000051","form_type":"8-K","ticker":"PCRX","cik":"0001396814","company_name":"Pacira BioSciences, Inc.","filed_at":"2025-04-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.158571+00:00","generated_at":"2026-05-23T19:32:29.301514+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"litigation","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Pacira settles EXPAREL patent litigation; Fresenius licensed to sell generic from early 2030","bullets":["Settlement with Fresenius Kabi, eVenus, Jiangsu Hengrui resolves all patent suits over EXPAREL (bupivacaine liposome).","Fresenius gets license to sell volume-limited generic starting on confidential date in early 2030, before last patent expiry in 2044.","Volume-limited percentages start at high-single-digit, increase to low-thirties in 2033, capped at high-thirties for final three years.","Unlimited generic license granted no earlier than 2039.","Pacira pays Fresenius $7 million for expected litigation cost savings."],"urls":{"canonical":"https://secwatch.observer/filing/0001396814-25-000051","json":"https://secwatch.observer/filing/0001396814-25-000051.json","markdown":"https://secwatch.observer/filing/0001396814-25-000051.md","text":"https://secwatch.observer/filing/0001396814-25-000051.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1396814/000139681425000051/0001396814-25-000051-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1396814/000139681425000051/pcrx-20250407.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T19:32:29.301514+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}